IE6 not supported.
no ssl-connection established.
please activate js.
zum Inhalt springen zur Suche springen zum Hauptmenü springen
AOP Orphan announces EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV) … read more here
PROUD-PV … … Ropeginterferon α-2b (AOP2014) versus Hydroxyurea in Polycythemia Vera
48 Study Centers in 13 Countries … … includes centers all across Europe: locate your study center
The Study Drugs … … find your information about the study drugs AOP2014 and Hydroxyurea
… is a randomized, multicenter, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia vera.
Learn more about PROUD-PV …
… are located all across Europe.
Find more information about the study centers…
… we provide some basic information about the study drugs AOP2014 (Ropeginterferon α-2b ) and Hydroxyurea.
Find your information …